Cancer-associated retinopathy associated with invasive thymoma.
OBJECTIVE
To report a case of cancer-associated retinopathy associated with invasive thymoma.


METHODS
Interventional case report.


METHODS
A 41-year-old Japanese woman was observed between February 1998 and May 2001. Ophthalmologic examinations and systemic examinations were performed. The patient received treatment including corticosteroid pulse therapy, plasmapheresis, and thymectomy.


RESULTS
The patient developed progressive visual dysfunction including bilateral visual acuity loss, concentric contraction of visual fields, and color vision loss. In both eyes, retinal vessel attenuation and retinal pigment epithelium degeneration were observed with fundus ophthalmoscopy and fluorescein angiography. Response in electroretinogram was reduced, suggesting both rod and cone dysfunction. Autoantibody against 23-kD cancer-associated retinopathy (CAR) antigen (antirecoverin antibody) was detected in the patient's serum. A mediastinal tumor that was histopathologically diagnosed as invasive thymoma was detected and was surgically resected. During more than 3 years of follow-up, no other malignancy was detected despite extensive systemic evaluation. The patient also suffered from subclinical myasthenia gravis. Although temporary improvement of visual function was observed after treatment with steroid pulse therapy and plasmapheresis' light perception of each eye was lost in the end.


CONCLUSIONS
The patient was diagnosed as having CAR. Invasive thymoma was considered to be the causative tumor because there had been no evidence that suggested other systemic malignancy during more than 3 years of follow-up.
Katsuta
Hideto
H
Department of Ophthalmology, Kurashiki Central Hospital, Okayama, Japan. katsuta@kuhp.kyoto-u.ac.jp
Okada
Morio
M
Nakauchi
Tadashi
T
Takahashi
Yutaka
Y
Yamao
Satoshi
S
Uchida
Sunao
S
D000328:Adult; D001323:Autoantibodies / Q000097:blood; D002135:Calcium-Binding Proteins / Q000276:immunology; D004596:Electroretinography; D005136:Eye Proteins; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use; D051597:Hippocalcin; D006801:Humans; D008074:Lipoproteins; D009157:Myasthenia Gravis / Q000150:complications; D009361:Neoplasm Invasiveness; D009419:Nerve Tissue Proteins; D010257:Paraneoplastic Syndromes / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D010956:Plasmapheresis; D020551:Pulse Therapy, Drug; D051603:Recoverin; D012164:Retinal Diseases / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D013934:Thymectomy; D013945:Thymoma / Q000150:complications* / Q000473:pathology / Q000628:therapy; D013953:Thymus Neoplasms / Q000150:complications* / Q000473:pathology / Q000628:therapy; D014786:Vision Disorders / Q000209:etiology; D014792:Visual Acuity
D001323:Autoantibodies; D002135:Calcium-Binding Proteins; D005136:Eye Proteins; D005938:Glucocorticoids; D008074:Lipoproteins; D009419:Nerve Tissue Proteins; C496731:RCVRN protein, human; D051603:Recoverin; D051597:Hippocalcin